Background: Intranasal decongestants such as oxymetazoline and xylometazoline are topical ?-adrenergic agonists widely used for nasal obstruction. Their short-term effects on olfactory perception and cognitive performance remain incompletely understood. Aim: To compare the acute effects of oxymetazoline, xylometazoline, and placebo nasal sprays on olfactory perception, short-term cognitive performance, and subjective nasal patency in healthy adults. Methods: In this randomized, double-blind, placebo-controlled, three-arm crossover pilot study, 24 healthy normosmic adults (18-35 years) received oxymetazoline 0.05%, xylometazoline 0.1%, and placebo (0.9% saline) in a Latin-square sequence with 48-hour washout periods. Olfactory perception (modified 5-item odor identification test and odor intensity visual analogue scale [VAS]), cognitive performance (5-word recall and Stroop test), and nasal patency (VAS) were assessed at baseline and 10, 30, and 60 minutes post-administration. Data were analyzed using repeated-measures ANOVA with Bonferroni correction.[KIMS/IEC/A320/M/2025, CTRI/2025/07/091690]. Results: All 24 participants (mean age 26.5±5.0 years; 50% female) completed the study. Odor identification scores did not differ significantly between treatments at any time point (all p>0.05). Odor intensity ratings were significantly lower with xylometazoline, with the greatest reduction observed at 30 minutes compared with oxymetazoline and placebo (p = 0.001). Both active treatments demonstrated higher 5-word recall scores than placebo at 10 minutes (p<0.001), although these differences were not sustained at later assessments. Stroop test performance did not differ significantly between treatments (all p>0.05). Subjective nasal patency improved significantly with both active treatments compared with placebo (all p<0.001), with earlier improvement observed with xylometazoline and greater improvement at 30 minutes with oxymetazoline. No significant carryover effects or clinically significant adverse events were observed. Conclusion: Oxymetazoline and xylometazoline significantly improved subjective nasal patency without affecting odor identification or attention. Xylometazoline reduced perceived odor intensity, and both agents were associated with transiently higher early recall scores. These findings suggest subtle time-dependent sensory and cognitive effects that warrant confirmation in larger studies.